Skip to contentpdufa.bio

mitapivat RISE

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

mitapivat RISE is an Agios Pharmaceuticals program in sickle cell disease. Its next catalyst is a Readout on Dec 12, 2026.

AGIO catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: sickle cell disease. Sponsor: Agios Pharmaceuticals (AGIO). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 12, 2026AGIO

Questions

When is mitapivat RISE's next FDA decision or readout?

The next tracked catalyst for mitapivat RISE is a Readout on Dec 12, 2026.

What happened at mitapivat RISE's most recent FDA decision?

No FDA decision for mitapivat RISE is in our archive yet.

What is mitapivat RISE used for?

In our records mitapivat RISE is under review or in development for sickle cell disease.

Who makes mitapivat RISE?

Agios Pharmaceuticals (AGIO).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.